Overview

Company Profile

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), is a late stage pharmaceutical company focused on the development and commercialization of Locilex®(pexiganan cream 0.8%), a potent and broad-spectrum topical antibiotic, for the treatment of mild and moderate skin and skin structure infections.

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) is late stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide for the treatment of  mild and moderate skin and skin structure infections.  Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers.  Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Dipexium Pharmaceuticals Investor Presentation

Investor Presentation

View our latest Corporate Presentation

View Presentation

Stock Snapshot

DPRX Symbol
NASDAQ Market
Market Cap
Price
Change
Volume
View Detailed Stock Data